Nevirapin (Nevirapine)

Nevirapine, the active ingredient in Nevirapin, is a non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It is employed in combination antiretroviral regimens to treat HIV‑1 infection in adults and children, helping to suppress viral replication and improve immune status.

GNH USA supplies Nevirapin as a licensed, GDP‑compliant international pharmaceutical supplier. The company provides the product to hospitals, pharmacies, and clinics worldwide, ensuring quality‑assured medication for antiretroviral programmes and supporting global HIV treatment initiatives and patient care.

Nevirapin is indicated for treatment of HIV‑1 infection as part of combination antiretroviral therapy.

- HIV‑1 infection: reduces viral load and improves immune function when used with other antiretroviral agents

Nevirapin may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Rash: mild to moderate skin eruption - Nausea: feeling of stomach upset - Fatigue: generalized tiredness - Headache: mild to moderate pain in the head - Dizziness: sensation of light‑headedness - Abdominal pain: discomfort in the stomach area - Elevated liver enzymes: mild increase in hepatic transaminases

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction with blistering - Toxic epidermal necrolysis: extensive skin detachment - Severe hepatotoxicity: marked liver injury, jaundice, or hepatitis - Hypersensitivity reactions: systemic symptoms such as fever and organ involvement - Hemolytic anemia: destruction of red blood cells - Severe rash: extensive or bullous skin eruptions

Before initiating therapy, clinicians should assess patient history and monitor for potential risks.

- Monitor liver function: obtain baseline and periodic liver‑function tests - Assess for hypersensitivity: discontinue if severe rash or systemic symptoms develop - Avoid in known nevirapine hypersensitivity: contraindicated in patients with prior reactions - Caution with hepatitis B or C: increased risk of liver injury - Pregnancy safety: risk unknown; weigh benefits against potential fetal harm - Store at room temperature: keep in original container, protect from moisture and heat

Nevirapin can interact with several medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Potent CYP3A4 inducers (e.g., rifampicin): may markedly reduce nevirapine levels - Co‑administration with hepatotoxic drugs (e.g., isoniazid): increases risk of liver injury - Use with other NNRTIs: may lead to additive toxicity

Moderate Interactions (Monitor Closely): - Protease inhibitors: may require dose adjustment of nevirapine - Anticoagulants (e.g., warfarin): potential alteration of INR values - Hormonal contraceptives: may reduce contraceptive effectiveness, requiring additional methods